Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer

Clinical Cancer Research

Volumn 11, Issue 10, 2005, Pages 3714-3721

  Atkins, Michael ^a,b   Regan, Meredith ^b   McDermott, David ^a,b   Mier, James ^a,b   Stanbridge, Eric ^c   Youmans, Amanda ^a   Febbo, Philip ^b   Upton, Melissa ^a   Lechpammer, Mirna ^b   Signoretti, Sabina ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; INTERLEUKIN 2; PARAFFIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL; TISSUE SECTION;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 21044442672     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2019     Document Type: Article

References (27)

1. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
2. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997;3 Suppl 1:S70-2.
3. Yang JC, Sherry RM, Stienberg SM, et al. A three-arm randomized comparison of high and low dose intravenous and subcutaneous interleukin-2 in the treatment of metastatic renal cancer. J Clin Oncol 2003;21:3127.
4. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
5. McDermott DF, Atkins MB. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther 2004;4:455-68.
6. Figlin R, Gitlitz B, Franklin J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 1997;3 Suppl 1:S92-7.
7. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:2566-75.
8. McDermott D, Parker R, Youmans A, et al. The effect of recent nephrectomy on treatment with high-dose interleukin-2 (HD IL-2) or subcutaneous (SC) IL-2/interferon alfa-2b (IFN) in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol Chicago (IL) 2003;22:385.
9. Upton MP, Parker R, Youmans AY, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005:28:In press.
10. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802-11.
11. Zavada J, Zavadova Z, Pastorekova S, Ciampor F, Pastorek J, Zelnik V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 1993;54:268-74.
12. Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92:1918-25.
13. Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fiuorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2000;18:4009-15.
14. Jonasch E, George D, Atkins MB. Renal Neoplasia. In: Brenner B, editor. Brenner and Rector's The Kidney. 7th ed. Philadelphia: Saunders; 2004. p. 1895-923.
15. Royal RE, Steinberg SM, Krouse RS, et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 1996;2:91.
16. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
17. Ivanov SV, Kuzmin I, Wei MH, et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A 1998;95:12596-601.
18. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158:905-19.
19. Parsa AT PI, Waldron JS, Sison CE, Pieper RO. PTEN disruption correlates with a clinically immunosuppressive phenotype in glioma: Akt-mediated regulation of B7-H1. Proceedings of AACR 2004:230.
20. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004;101:17174-9.
21. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
22. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18.
23. George D, Michaelson MD, Oh W, et al. Phase I study of PTK787/ZK 222584 in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol Chicago (IL) 2003;22:385.
24. Ratain MJ, Flaherty KT, Stadler WM, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). Proc Am Soc Clin Oncol New Orleans (LA) 2004;23:381.
25. Motzer RJ, Rini BI, Michaelson MDea. SUO11248, A novel tyrosine kinase inhibitor shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase 2 trial. Proc Am Soc Clin Oncol New Orleans (LA) 2004;23:381.
26. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of Interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-67.
27. Royston P, Sauerbrei W, Ritchie A. Is treatment with interferon-α effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer 2004;90:794-9.